RE:Only 1 analyst It must be complete speculation at this point to put a price on the company"s worth if you aren't in "the know". I think everone knows at this point (or hopes) that the SP is undervaled, but by how much?, is anyone's guess.
When I re-read an excerpt from the first quarter results that stuck with me (see below) you'd think that PROMIS is sitting on THE HOLY GRAIL of cures for pathology as a whole, and maybe they do, who knows, but if so, why haven't they partnered with anyone or clinched the $$$ (besides the Boston group) to move forward?
"In addition, in collaboration with Dr. David Wishart of the University of Alberta, we have enhanced and extended our unique technology platform. ProMIS Neurosciences has a unique antibody design capability, which not even the largest pharmaceutical companies have to the best of our knowledge based on ongoing discussions with them. We are able rapidly and cost effectively to design and create antibodies or therapeutic vaccines that only target toxic, mis-folded versions of proteins that otherwise play a normal healthy role. This capability has given ProMIS a growing portfolio of potential “best in class” monoclonal antibodies (or corresponding therapeutic vaccines), including our lead program PMN310, targeting toxic oligomers of amyloid in Alzheimer’s. In the Alzheimer’s field, positive results or regulatory steps were announced by Lilly, Cassava, and Biogen, all of which support the science suggesting PMN310 may be “best in class"
If we assume for a moment that PROMI'S science is valid (which we all hope) then the only conclusion I can come to is that the company is asking way to much(SSS) or the conditions simply do not suit the big pharmas. So, the real question here is ''HOW MUCH IS THE TOO MUCH?'' and on what terms?